Senti Biosciences (SNTI) Operating Expenses (2021 - 2025)

Senti Biosciences has reported Operating Expenses for 5 years, with the latest figure at $18.7 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 15.41% year-over-year to $18.7 million; the trailing twelve-month figure through Dec 2025 stood at $68.8 million (up 12.72% YoY), and the FY2025 full-year result was $68.8 million, up 12.72% from the prior year.
• Operating Expenses for Q4 2025 stood at $18.7 million, up from $16.9 million in the prior quarter.
• The five-year high for Operating Expenses was $44.2 million in Q3 2023, with the low at $1178.0 in Q1 2021.
• Average Operating Expenses over 5 years is $16.4 million, with a median of $16.3 million recorded in 2023.
• Year-over-year, Operating Expenses jumped 1091750.59% in 2022 and plunged 65.59% in 2024.
• Tracing SNTI's Operating Expenses over 5 years: stood at $11.7 million in 2021, then jumped by 44.31% to $16.9 million in 2022, then gained by 10.95% to $18.7 million in 2023, then slipped by 13.54% to $16.2 million in 2024, then advanced by 15.41% to $18.7 million in 2025.
• The last three Operating Expenses figures came in at $18.7 million (Q4 2025), $16.9 million (Q3 2025), and $16.8 million (Q2 2025), per Business Quant data.

Peer Comparison